Demonstration of focal physiologic in-vivo somatostatin receptor expression in the caput epididymis of the testes on 68Ga-DOTANOC PET/CT and 177Lu-DOTATATE post-therapy whole body scintigraphy

Document Type : Case report


1 Departments of Nuclear Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India

2 Department of Radiodiagnosis, Post Graduate Institute of Medical Education and Research, Chandigarh, India


We present the case of a 60-year-old man with metastatic neuroendocrine tumor of the ileum following ileal resection, being evaluated for 177Lu-based peptide receptor radionuclide therapy. 68Ga-DOTANOC PET/CT showed focal increased tracer uptake in the scrotal region without any morphologic changes on the corresponding CT images. Similar increased tracer uptake was seen on post-therapy whole-body imaging following 177Lu-DOTATATE therapy. An USG guided FNA revealed no malignant cells on cytopathologic examination. This case illustrates that focal testicular tracer uptake, may not always be pathological and can represent a normal physiologic variant, similar to the diffuse testicular somatostatin receptor expression as previously reported in literature.


  1. Ambrosini V, Campana D, Bodei L, Nanni C, Castellucci P, Allegri V, et al. 68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors. J Nucl Med. 2010; 51: 669–673.
  2. Wild D, Mäcke HR, Waser B, Reubi J C, Ginj M, Rasch H, Müller-Brand J, et al. 68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5. Eur J Nucl Med Mol Imaging. 2005; 32:724–724.
  3. Sharma P, Dhull VS, Arora S, Gupta P, Kumar R, Durgapal P, et al. Diagnostic accuracy of 68Ga-DOTANOC PET/CT imaging in pheochromocytoma. Eur J Nucl Med Mol Imaging. 2014; 41: 494–504.
  4. Parihar AS, Mittal BR, Vadi SK, Basher RK, Bhansali A. Ectopic Cushing Syndrome (ECS). Clin Nucl Med. 2018; 43:769–770.
  5. Ashwathanarayana AG, Biswal CK, Sood A, Parihar AS, Kapoor R, Mittal BR. Imaging-guided use of combined 177Lu-DOTATATE and capecitabine therapy in metastatic mediastinal paraganglioma. J Nucl Med Technol. 2017; 45:314–316.
  6. Sharma P, Mukherjee A, Bal C, Malhotra A, Kumar R. Somatostatin Receptor–Based PET/CT of Intracranial Tumors: A Potential Area of Application for 68Ga-DOTA Peptides? Am J Roentgenol. 2013; 201:1340–1347.
  7. Parihar A S, Basher R K, Rana N, Mittal B R. Incidental Meningioma on 68Ga-DOTANOC Positron-Emission Tomography. Indian J Nucl Med. 2018; 33:182.
  8. Vadi SK, Mittal BR, Parihar AS, Kumar R, Singh H, Singh G. 68Ga-DOTANOC PET/CT in an Atypical Extraskeletal Paravertebral Hemangioma Mimicking as Neurogenic Tumor in a Known Case of Breast Cancer. Clin Nucl Med. 2019; 44:E364–E366.
  9. Pettinato C, Sarnelli A, Di Donna M, Civollani S, Nanni C, Montini G, et al. 68Ga-DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2008; 35:72–79.
  10. Wild D, Bomanji JB, Benkert P, Maecke H, Ell PJ, Reubi JC, et al. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors. J Nucl Med. 2013; 54:364–372.
  11. Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: Comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 2007;48:508–518.
  12. Hofmann M, Maecke H, Börner R, Weckesser E, Schöffski P, Oei L, et al. Biokinetics and imaging with the somatostatin receptor PET radioligand 68Ga-DOTATOC: Preliminary data. Eur J Nucl Med. 2001; 28:1751–1757.
  13. Al-Ibraheem A, Bundschuh RA, Notni J, Buck A, Winter A, Wester HJ, et al. Focal uptake of  68Ga-DOTATOC in the pancreas: Pathological or physiological correlate in patients with neuroendocrine tumours? Eur J Nucl Med Mol Imaging. 2011; 38:2005–2013.
  14. Hofman MS, Eddie Lau WF, Hicks RJ. Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: Clinical utility, normal patterns, pearls, and pitfalls in interpretation1. Radiographics. 2015; 35:500–516.
  15. Baou N, Bouras M, Droz JP, Benahmed M, Krantic S, et al. Evidence for a selective loss of somatostatin receptor subtype expression in male germ cell tumors of seminoma type. Carcinogenesis. 2000; 21:805–810.Kagna O, Pirmisashvili N, Tshori S, Freedman N, Israel O, Krausz Y, et al. Neuroendocrine Tumor Imaging with 68Ga-DOTA-NOC: Physiologic and Benign Variants. Am J Roentgenol. 2014; 203:1317–1323.
  16. Todorović-Tirnanić MV, Gajić MM, Obradović VB, Baum RP, et al. Gallium-68 DOTATOC PET/CT in vivo characterization of somatostatin receptor expression in the prostate. Cancer Biother Radiopharm. 2014; 29:108–115.
  17. Degnan AJ, Tadros SS, Tocchio S. Pediatric Neuroendocrine Carcinoid Tumors: Review of Diagnostic Imaging Findings and Recent Advances. Am J Roentgenol. 2017; 208:868–877.
  18. Carreras C, Kulkarni HR, Baum RP. Rare Metastases Detected by 68Ga-Somatostatin Receptor PET/CT in Patients with Neuroendocrine Tumors. Recent Results Cancer Res. 2013. 379–384.